APP and Alzheimer disease: BACE-1 (β-site amyloid precursor protein cleaving enzyme 1) inhibitors have been explored as potential AD therapeutics due to their ability to suppress Aβ production by preventing the cleavage of amyloid precursor protein (APP) into β-fragments, which are subsequently processed by γ-secretase to form Aβ [12].